Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361196 | 0.84 | SRC (0.39) | CSF1REGFRKCNH2ERBB2MAP4K4 | |
| SCHEMBL3278716 | 0.82 | SRC (0.39) | CSF1REGFRKCNH2ERBB2MAP4K4 | |
| SCHEMBL22013370 | 0.82 | KCNH2 (0.38) | CSF1REGFRKCNH2ERBB2MAP4K4 | |
| SCHEMBL2040415 | 0.80 | EGFR (0.43) | EGFRKCNH2MAP4K4 | |
| SCHEMBL3272833 | 0.79 | CSF1R (0.38) | CSF1REGFRKCNH2ERBB2MAP4K4 | |
| SCHEMBL2489719 | 0.78 | EGFR (0.42) | CSF1REGFRKCNH2MAP4K4 | |
| SCHEMBL2949290 | 0.77 | MAP4K4 (0.41) | EGFRKCNH2MAP4K4 | |
| SCHEMBL29692870 | 0.77 | EGFR (0.41) | EGFRKCNH2 | |
| SCHEMBL1075499 | 0.77 | EGFR (0.41) | EGFRKCNH2MAP4K4 | |
| SCHEMBL29692882 | 0.77 | EGFR (0.41) | EGFRKCNH2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882247-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020098723-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | 上海轶诺药业有限公司 | 2020-05-22 | — | — | WO | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2723737-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| EP-2041145-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | CSF1R 3805/4885EGFR 3139/4885KCNH2 1381/4885 |
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | AADAC, AZI2, NNMT | CSF1R 3575/4885EGFR 2028/4885KCNH2 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.